Twitter Facebook LinkedIn YouTube

New Listing: RAMM Pharma Corp. (CSE:RAMM)

Video Platform Video Management Video Solutions Video Player

RAMM is one of the leaders in the field of cannabinoid pharmacology and product formulation for cannabis-derived prescription drugs and registered products.

Additional Information:

Company: RAMM Pharma Corp
Website: http://RAMM Pharma Corp
Stock Symbol: CSE: RAMM
Date Published: Nov 8, 2019
Transcript: Available

Video Transcript:

I’m Erica James for Investmentpitch Media

RAMM Pharma Corp. is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “RAMM”.

RAMM is one of the leaders in the field of cannabinoid pharmacology and product formulation for cannabis-derived prescription drugs and registered products.

Founded in 1988 in Montevideo, Uruguay, RAMM is an established pharmaceutical and medical product business.

In 2017 the company received approval for its first plant-derived cannabinoid pharmaceutical drug from Uruguay’s Ministry of Health.

RAMM currently sells five cannabis based registered products commercially in Uruguay under two brands.

It also has a pipeline of new products in various stages of approval and development.

Its products have also been approved for use on a compassionate basis in 3 other Latin American countries and are in the application process at various stages of approval in several other countries.

Latin America alone has a population of 639 million 350 million of which live in a jurisdiction with medical cannabis legislation in place or pending.

RAMM’s formulation and manufacturing is conducted at its state-of-the-art Good Manufacturing Practices (GMP) certified cannabis formulation facility ideally situated within close proximity to an international airport and other export hubs.

The facility totals approximately 36,600 square feet and features dedicated cannabis and medical product laboratories along with packaging capabilities and storage/distribution facilities.

The company is also in the process of establishing vertically integrated operations through the development of its large-scale cultivation facility.

The company’s approximately 7 hectare property, one of the largest greenhouse facilities in Uruguay, contains approximately 2 hectares of enclosed greenhouse facility with an additional 3 hectares of expansion space available.

In addition to RAMM’s industry leading activities in the field of cannabinoid pharmaceuticals, RAMM also operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been in operations for 30 years.

Jack Burnett, CEO, stated: “Our public listing marks a significant milestone as RAMM continues to establish itself as a leader in the development and commercialization of cannabis-derived prescription drugs and registered products to meet the growing demand in Latin America and other jurisdictions globally. We are very pleased with the interest in our suite of products and look forward to increasing access to their therapeutic benefits as we continue to expand our product offerings, awareness and availability.”

The company raised gross proceeds of approximately $35.3 million from a non-brokered private placement of approximately 26.2 million shares priced at $1.35 per share.

The shares are trading at $0.62.

For more information, please visit the company’s website C, contact Guillermo Delmonte, COO, at 484-474-0932 or by email at

I’m Erica James for Investmentpitch Media